RecruitingNot ApplicableNCT07304076

Clinical Research on the Comparative Effectiveness and Safety of JHG002 Therapy for Chronic Low Back Pain: A Multicenter Randomized Controlled Trial

Sponsor

Jaseng Medical Foundation

Enrollment

96 participants

Start Date

Dec 17, 2025

Study Type

INTERVENTIONAL

Conditions

Chronic Low Back Pain (CLBP)

Summary

A multicenter randomized controlled trial

Eligibility

Min Age: 19 YearsMax Age: 70 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Hominis placental pharmacopuncture and a medical device called Tanscutaneous electrical nerve stimulation (TENS) for people with chronic low back pain (clbp). The study is currently recruiting participants at 4 locations. People eligible for this study include aged 19 Years to 70 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGHominis placental pharmacopuncture

JHG002 pharmacopuncture is a purified Hominis placenta extract formulated for injection at acupuncture points. In Korean medicine, Hominis placenta has traditionally been used to support vitality, relieve chronic pain, and enhance functional recovery.

DEVICETanscutaneous electrical nerve stimulation (TENS)

Transcutaneous electrical nerve stimulation is a non-invasive physical therapy that delivers low-intensity electrical stimulation to the lumbar area to reduce pain and muscle tension.